MedTrace Logo

Phase II Dasatinib Study in Advanced Breast Cancer

NCT00546104 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2013-07-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if dasatinib will safely reduce the size or spread of your tumor.

Conditions

Interventions

DRUG

Dasatinib

An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.

Sponsors & Collaborators

Principal Investigators

  • Kimberly Blackwell, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546104 on ClinicalTrials.gov